Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The combination of GLP-1 and GIP activation explains why dual agonists like Tirzepatide outperform single GLP-1 agonists for both weight and glucose outcomes
It was noted that no clinical trials had yet been completed on AD, PD, or other neurodegenerative disorders
We recommend using GLP-1 Revive throughout your GLP-1 journey
Novo Nordisk's NovoCare and Eli Lilly's LillyDirect programs both offer direct-to-consumer pricing for cash-pay patients, with monthly costs that have come down meaningfully from peak 2024 levels
Studies of tirzepatide (Zepbound and Mounjaro) have found similar patterns
US$ 22.71
US$ 21.42
US$ 26.59
US$ 26.52
US$ 21.75
